Borchard, S. ; Raschke, S.* ; Zak, K.M. ; Eberhagen, C. ; Einer, C. ; Weber, E. ; Müller, S.M.* ; Michalke, B. ; Lichtmannegger, J. ; Wieser, A. ; Rieder, T.* ; Popowicz, G.M. ; Adamski, J. ; Klingenspor, M.* ; Coles, A.H.* ; Viana, R.* ; Vendelbo, M.H.* ; Sandahl, T.D.* ; Schwerdtle, T.* ; Plitz, T.* ; Zischka, H.
Bis-choline tetrathiomolybdate prevents copper-induced blood-brain barrier damage.
Life Sci. All. 5:e202101164 (2022)
In Wilson disease, excessive copper accumulates in patients' livers and may, upon serum leakage, severely affect the brain according to current viewpoints. Present remedies aim at avoiding copper toxicity by chelation, for example, by D-penicillamine (DPA) or bis-choline tetrathiomolybdate (ALXN1840), the latter with a very high copper affinity. Hence, ALXN1840 may potentially avoid neurological deterioration that frequently occurs upon DPA treatment. As the etiology of such worsening is unclear, we reasoned that copper loosely bound to albumin, that is, mimicking a potential liver copper leakage into blood, may damage cells that constitute the blood-brain barrier, which was found to be the case in an in vitro model using primary porcine brain capillary endothelial cells. Such blood-brain barrier damage was avoided by ALXN1840, plausibly due to firm protein embedding of the chelator bound copper, but not by DPA. Mitochondrial protection was observed, a prerequisite for blood-brain barrier integrity. Thus, high-affinity copper chelators may minimize such deterioration in the treatment of neurologic Wilson disease.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Relative Exchangeable Copper; Wilson Disease Gene; Ammonium Tetrathiomolybdate; D-penicillamine; Rat Model; Serum; Zinc; Ceruloplasmin; Binding; Metal
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2022
Prepublished im Jahr
2021
HGF-Berichtsjahr
2021
ISSN (print) / ISBN
2575-1077
e-ISSN
2575-1077
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 5,
Heft: 3,
Seiten: ,
Artikelnummer: e202101164
Supplement: ,
Reihe
Verlag
EMBO Press
Verlagsort
Heidelberg
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
POF Topic(s)
30203 - Molecular Targets and Therapies
30202 - Environmental Health
30201 - Metabolic Health
Forschungsfeld(er)
Enabling and Novel Technologies
Environmental Sciences
Radiation Sciences
Genetics and Epidemiology
PSP-Element(e)
G-505200-003
G-503000-001
G-505200-001
G-505293-001
G-504800-002
G-501391-001
G-500600-001
Förderungen
Wilson Therapeutics AB/Alexion AstraZeneca Rare Disease
Morbus Wilson e.V.
Copyright
Erfassungsdatum
2021-12-07